On Monday, Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) was -4.12% drop from the session beforebefore settling in for the closing price of $1.70. A 52-week range for LXRX has been $0.92 – $3.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 186.21%. When this article was written, the company’s average yearly earnings per share was at 14.47%. With a float of $349.01 million, this company’s outstanding shares have now reached $361.49 million.
Considering the fact that the conglomerate employs 285 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 80.66%, operating margin of -5412.11%, and the pretax margin is -5509.34%.
Lexicon Pharmaceuticals Inc (LXRX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lexicon Pharmaceuticals Inc stocks. The insider ownership of Lexicon Pharmaceuticals Inc is 3.45%, while institutional ownership is 76.85%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000. Before that another transaction happened on Nov 16 ’23, when Company’s Chief Executive Officer bought 90,000 for $1.05, making the entire transaction worth $94,797. This insider now owns 914,359 shares in total.
Lexicon Pharmaceuticals Inc (LXRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 14.47% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
You can see what Lexicon Pharmaceuticals Inc (LXRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 11.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 161.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.77, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Compared to the last year’s volume of 3.48 million, its volume of 1.41 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 51.42%. Additionally, its Average True Range was 0.11.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 15.46%, which indicates a significant decrease from 22.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.38% in the past 14 days, which was lower than the 79.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8276, while its 200-day Moving Average is $1.8496. Nevertheless, the first resistance level for the watch stands at $1.6833 in the near term. At $1.7367, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7733. If the price goes on to break the first support level at $1.5933, it is likely to go to the next support level at $1.5567. Should the price break the second support level, the third support level stands at $1.5033.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
There are 246,237K outstanding shares of the company, which has a market capitalization of 589.23 million. As of now, sales total 1,200 K while income totals -177,120 K. Its latest quarter income was 1,650 K while its last quarter net income were -53,430 K.
